Sugi Predict

Sugi Predict / Compounds / SCHEMBL23966783

SCHEMBL23966783

SCHEMBL23966783

Nc1c(F)cc(-c2cn(C3CC3)c3ncnc(N)c23)cc1F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 11/20 0.70
▸ SRC P12931 9/20 0.67
▸ ABL1 P00519 7/20 0.60
▸ EGFR P00533 7/20 0.60
▸ ABL2 P42684 7/20 0.60
▸ PDGFRB P09619 2/20 0.59
▸ KIT P10721 2/20 0.59
▸ FLT3 P36888 2/20 0.59
▸ SIK1 P57059 1/20 0.59
▸ RIPK4 P57078 1/20 0.59
▸ DDR1 Q08345 1/20 0.59
▸ RIPK1 Q13546 1/20 0.59
▸ DSTYK Q6XUX3 1/20 0.59
▸ RIPK3 Q9Y572 1/20 0.59
▸ RET P07949 2/20 0.57
▸ JAK2 O60674 1/20 0.57
▸ NTRK1 P04629 1/20 0.57
▸ INSR P06213 1/20 0.57
▸ LCK P06239 1/20 0.57
▸ NPM1 P06748 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23966923 0.86 RIPK2 (0.91) RIPK2SRCABL1EGFRABL2
SCHEMBL29998925 0.86 RIPK2 (0.91) RIPK2SRCABL1EGFRABL2
SCHEMBL29999326 0.82 RIPK2 (0.84) RIPK2SRCABL1EGFRABL2
SCHEMBL2075045 0.82 RIPK2 (0.84) RIPK2SRCABL1EGFRABL2
SCHEMBL23966761 0.82 RIPK2 (0.84) RIPK2SRCABL1EGFRABL2
SCHEMBL23966902 0.82 RIPK2 (0.60) RIPK2SRCABL1EGFRABL2
SCHEMBL24072623 0.82 RIPK2 (0.69) RIPK2SRCPDGFRBKITFLT3
SCHEMBL23966913 0.81 SRC (0.73) RIPK2SRCABL1EGFRABL2
SCHEMBL23966766 0.81 RIPK2 (0.65) RIPK2SRCABL1EGFRABL2
SCHEMBL20351628 0.80 SRC (0.80) RIPK2SRCABL1EGFRABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12091413-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2024-09-17 — — US disclosed
EP-4146348-B1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2024-07-03 — — EP disclosed
US-20230416259-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2023-12-28 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
CN-115843272-A Inhibitors of NEK7 kinase 哈利亚治疗公司 2023-03-24 — — CN disclosed
EP-4146348-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2023-03-15 — — EP disclosed
US-20220064173-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2022-03-03 — — US disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 — — WO disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 — — WO disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 — — US disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 — — US disclosed
WO-2021226547-A2 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. (US) 2021-11-11 — — WO disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 — — US disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355130-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-12091413-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 RIPK2 23/4885SRC 3388/4885ABL1 4556/4885
US-11161852-B1 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20230416259-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20220064173-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.